{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T05:50:37Z","timestamp":1720504237100},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T00:00:00Z","timestamp":1297123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1756-9966-30-16","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T15:06:57Z","timestamp":1297177617000},"source":"Crossref","is-referenced-by-count":6,"title":["FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases"],"prefix":"10.1186","volume":"30","author":[{"given":"Francesco","family":"Pisani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Ludovico","family":"Maini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Sciuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dessanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Assisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Petti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"435_CR1","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/cncr.21882","volume":"106","author":"CS Tam","year":"2006","unstructured":"Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin IK, Carney D, Seymour JF: Fludarabine, Cyclophosphamide, and Rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin's lymphoma. Cancer. 2006, 106: 2412-2420. 10.1002\/cncr.21882.","journal-title":"Cancer"},{"key":"435_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","volume":"23","author":"MS Czuczman","year":"2005","unstructured":"Czuczman MS, Koryzna A, Mohr A, Stewart C, Danohue K, Blumenson L, Bemstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippestein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bemstein SH: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005, 23: 694-704. 10.1200\/JCO.2005.02.172.","journal-title":"J Clin Oncol"},{"key":"435_CR3","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PL, Kolstad A, d'Amore F, Diaz MG, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A: Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008, 26: 5156-5164. 10.1200\/JCO.2008.17.2015.","journal-title":"J Clin Oncol"},{"key":"435_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","volume":"14","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof-Delaloye A: Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence. The Oncologist. 2009, 14: 17-29. 10.1634\/theoncologist.2009-S2-17.","journal-title":"The Oncologist"},{"key":"435_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzing","year":"2003","unstructured":"Witzing TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS: Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003, 21: 1263-1270. 10.1200\/JCO.2003.08.043.","journal-title":"J Clin Oncol"},{"key":"435_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C Emmanouilides","year":"2006","unstructured":"Emmanouilides C, Witzing TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A: Treatment with Yttrium-90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006, 47: 629-636. 10.1080\/10428190500376076.","journal-title":"Leuk Lymphoma"},{"key":"435_CR7","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzing","year":"2007","unstructured":"Witzing TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with Yttrium-90 ibritumomab tiuxetan. Cancer. 2007, 109: 1804-1810. 10.1002\/cncr.22617.","journal-title":"Cancer"},{"key":"435_CR8","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","volume":"23","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Kostakoglu L, Chadbum A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131-tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005, 23: 5696-5704. 10.1200\/JCO.2005.14.803.","journal-title":"J Clin Oncol"},{"key":"435_CR9","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI: Phase II trial of CHOP chemotherapy followed by I-131-tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five years follow up of Southwest Oncology Group Protocol 59911. J Clin Oncol. 2006, 24: 4143-4129. 10.1200\/JCO.2006.05.8198.","journal-title":"J Clin Oncol"},{"key":"435_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cncr.22740","volume":"110","author":"S Sacchi","year":"2007","unstructured":"Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M: Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007, 110: 121-128. 10.1002\/cncr.22740.","journal-title":"Cancer"},{"key":"435_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","volume":"86","author":"M Dreyling","year":"2007","unstructured":"Dreyling M, Trumper L, von Schilling C, Rummel M, Holtkamp U, Waldmann A, Wehmeyer J, Freund M: Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma - Role of radioimmunotherapy. Ann Hematol. 2007, 86: 81-87. 10.1007\/s00277-006-0207-0.","journal-title":"Ann Hematol"},{"key":"435_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ejca.2007.12.008","volume":"44","author":"PL Zinzani","year":"2008","unstructured":"Zinzani PL, d'Amore F, Bombardieri E, Brammer E, Codina JG, Ilidge T, Jurczak W, Linkesch W, Morschhauser F, Vandenberghe E, Van Hoof A: Consensus conference: Implementing treatment recommendations on Yttrium-90 immunotherapy in clinical practice - Report of a European workshop. Eur J Cancer. 2008, 44: 366-373. 10.1016\/j.ejca.2007.12.008.","journal-title":"Eur J Cancer"},{"key":"435_CR13","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanoulides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A: Treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007, 25: 4285-4292. 10.1200\/JCO.2006.09.2882.","journal-title":"J Clin Oncol"},{"key":"435_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdq024","volume":"21","author":"E Lopci","year":"2010","unstructured":"Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, Bell\u00f2 M, Botto M, Huglo D, Morschhauser F, Zinzani PL, Fanti S: FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y-90: multicentric study. Ann Oncol. 2010, 21: 1877-1883. 10.1093\/annonc\/mdq024.","journal-title":"Ann Oncol"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-30-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-30-16\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-30-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T08:22:22Z","timestamp":1548231742000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-30-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-30-16","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,8]]},"article-number":"16"}}